# Nigella sativa (Habbatus sauda): The Perspectives For COVID-19 Treatment

F Amin, M Sari, Z Amin

**Citation**

F Amin, M Sari, Z Amin. *Nigella sativa (Habbatus sauda): The Perspectives For COVID-19 Treatment*. The Internet Journal of Infectious Diseases. 2020 Volume 18 Number 1.

**DOI:** 10.5580/IJID.55091

**Abstract**

**Background:** *Nigella sativa* may have the potency to complement integrally in conditions of uncertain core basic needs of COVID-19 treatment. The understanding of immune responses occurring in the mechanism of COVID-19 caused by SARS-CoV-2 infection has brought attention to the more specific demand on the potential drug targeted for the treatment of patients with COVID-19.

**Discussion:** The core basic needs in the treatment of COVID-19, based on the immune responses, that encompassing all the stage of diseases going through preventive until curative aspects consist of increased immunity using interferon; lung protective function; anti-inflammatory by interferon- activation; and inhibition of hyaluronan-synthase-2 by 4-methylumbelliferone. *Nigella sativa* may give a role in all four core basic needs from the viewpoint of immune responses occurring in COVID-19 infection.

**Conclusions:** *Nigella sativa* may have the potency as a complementary therapy that may be applied in all stages of the core basic needs of COVID-19 treatment, which the scientific community may more consider its broad-range potential benefit of use in the COVID-19 treatment research.

## INTRODUCTION

*Nigella sativa* (also said as *Habbatus sauda* or black cumin) is a "wonder" herb from the Ranunculaceae family renowned as the remedy with a broad pharmacological spectrum of benefit [1]. *Nigella sativa* may have the potency to complement integrally in conditions of uncertain core basic needs of COVID-19 treatment. The integral role of *Nigella sativa* that may engage in the core basic needs of COVID-19 treatment, in our view, is comprehensible based on two-phase of immune responses [2] induced by COVID-19 infection. This understanding of immune responses occurring in the mechanism of COVID-19 caused by SARS-CoV-2 infection has brought attention to the more specific demand in research on the potential drug targeted for the treatment of patients with COVID-19.

## DISCUSSION

The immunomodulatory ability of *Nigella sativa*, as a single-alternative therapy already provenly improving viral load in patients with Hepatitis C virus (HCV) that were not eligible for therapy with interferon (IFN)/ribavirin [3], explained by significantly increasing macrophages and CD4+ T cells [4] along with significantly decreasing viral titer and increasing serum IFN levels [5], to our view, shows its potency to have a role in phase I of immune response encompassing asymptomatic and incubation period on the first stage of COVID-19 course and non-severe illness period of the second stage [6], which emphasizes the core basic need of immune protection by immune-boosting treatment, either utilizing IFN or antisera [2].

The in vitro antiviral activity mechanism of *Nigella sativa* has further known suggested decreasing the replication of the coronavirus and the virus load [7]. Of prominent, *Nigella sativa* is noted to be safe and side-effects are unremarkable. Therefore, *Nigella sativa* is considered usable for self-treatment, as an advantage consideration in the perspectives of preventive therapy in light to the quest of beneficial immunization in the field of SARS-CoV-2 vaccine research. In relation to this, the antiviral activity of *Nigella sativa* has also been demonstrated against cytomegalo virus infection; avian influenza (H9N2); Chistosoma Mansoni infection; Peste des petits ruminants (PPR) virus; Broad Bean Mosaic virus; human immunodeficiency virus (HIV); Zucchini

Yellow Mosaic virus; Papaya Ring Spot virus [8] and the thymoquinone component of Nigella sativa is known to repress p16 protein and generate G1 phase cell cycle arrest in infected cells by human papillomavirus [9].

Furthermore, the *Nigella sativa* ability potency in exerting the required anti-inflammatory effects by activating IFN [5], in our notion, may also be advantageous for another core basic need of COVID-19 treatment because very severe patients may not have this activation ability due to T cells are not activated properly by infection of SARS-CoV-2 in phase II of the immune response [2], which is dominated by the cytokine release syndrome (CRS) that cause cytokine storms and, as a result, lung damage due to lung inflammation, defining severe conditions in the third stage of the disease course [6]. Rapid commencement of extensive inflammation in the lungs and, consequently, leading to the fatality, showing white patches characteristics in CT scan images known as "ground glass" indicating clear liquid jelly resembled wet drowning-lungs. The presence of the fluid may be explained from acute respiratory distress syndrome (ARDS) occurring that relates to hyaluronan (HA) [10], which capable to absorb water until 1000 times greater its molecular weight [11].

The inflammatory cytokines' (tumour necrosing factor (TNF), interleukin (IL)-1) levels are notably high in the COVID-19 patients' lungs, which these cytokines are strong activators of HA-synthase-2 (HAS2) [11]. *Nigella sativa*, trough its thymoquinone component, known to generate the release of free 4-methylumbelliferone (4-MU) [9], an inhibitor of HAS2 as we notice, one core basic need mostly-overlook in COVID-19 treatment [2]. The efficacy of *Nigella sativa* in the prevention and treatment of inflammatory diseases has also been shown by the action of its thymoquinone component on inflammatory signalling pathways encompassing nuclear factor kappa B (NF-kB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor gamma (PPAR-), and protein kinase B (AKt), and apoptosis; pro-inflammatory mediators/cytokines; antioxidant enzymes and reactive oxygen species systems [12].

Of equally important, *Nigella sativa* has invaluable lung protector capacity [13], one of the core basic need in COVID-19 treatment [2], which in our view, applicable to prevent lung tissue further deteriorate and damage, which worthwhile to initiate even in asymptomatic persons and, substantial, in patients who yet not severely-infected.

## CONCLUSIONS

*Nigella sativa* denotes indispensable potency to complement integrally that may be applied for all four core basic needs of COVID-19 treatment encompassing increased immunity using IFN; lung protective function; anti-inflammatory by IFN activation and inhibition of HAS2 by 4-MU. The scientific community may more consider the broad-range potential benefit of the use of *Nigella sativa* in COVID-19 treatment research.

## ABBREVIATIONS

Akt: Protein kinase B

ARDS: Acute respiratory distress syndrome

COVID-19: Coronavirus disease 2019

CRS: Cytokine release syndrome

CT-scan: Computed tomography scan

HA: hyaluronan

HAS-2: HA-synthase-2

HCV: Hepatitis C virus

HIV: Human immunodeficiency virus

IFN: Interferon

IFN: Interferon 

IL-1: Interleukin 1

MAPK: Mitogen-activated protein kinase

NF-kB: Nuclear factor kappa B

PPAR-: Peroxisome proliferator-activated receptor gamma

PPR: Peste des petits ruminants

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

STAT3: Signal transducer and activator of transcription 3

TNF: Tumour necrosing factor

4-MU: 4-methylumbelliferone

### References

[1]. Al-Bukhari I. Book of medicine: hadith 592. In: Khan, MM. Sahih al-Bukhari. Riyadh: Darussalam; 1999.
[2]. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses.

Cell Death Differ. 2020; doi:10.1038/s41418-020-0530-3.
[3]. Barakat EM, El Wakeel LM, Hagag RS. Effects of Nigella sativa on outcome of hepatitis C in Egypt. World J Gastroenterol. 2013;19:2529-36.
[4]. Salem ML, Hossain MS. In vivo acute depletion of CD8(+) T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. Int J Immuno-pharmacol. 2000;22:707-18.
[5]. Ciccone E, Viale O, Pende D, Malnati M, Biassoni R, Melioli G, et al. Specific lysis of allogeneic cells after activation of CD3-lymphocytes in mixed lymphocyte culture. J Exp Med. 1988;168:2403-8.
[6]. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; doi:10.1001/jama.2020.1585.
[7]. Ulasli M, Gurses SA, Bayraktar R, Yumrutas O, Oztuzcu S, Igci M, et al. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep. 2014;41:1703-11.
[8]. Molla S, Azad MAK, Hasib MAAA, Hossain MM, Ahammed MS, Rana S, et al. A review on antiviral effects of Nigella sativa l. Pharmacol Online. 2019;2:47-53.
[9]. Finlay, TM: Thymoquinone as a novel ligand which activates neu4 sialidase to promote a pro-inflammatory response.
https://qspace.library.queensu.ca/bitstream/handle/1974/1770/Finlay_Trisha_M_200904_MSc.pdf?sequence=1&isAllowed=y (2009). Accessed 02 Apr 2020.
[10]. Hallgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis. 1989;139:682-7.
[11]. Bell TJ, B O, Morgan DJ, Salek-Ardakani S, Jagger C, Fujimori T, et al. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol. 2018;80:14-28.
[12]. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443-51.
[13]. Hossein BM, Nasim V, Sediqa A. The protective effect of Nigella sativa on lung injury of sulfur mustard-exposed Guinea pigs. Exp Lung Res. 2008;34:183-94.

## Author Information

**Firman Zulkifli Amin**
Faculty of Medicine, Universitas Indonesia
Jakarta, Indonesia

**Mila Kurnia Sari**
Faculty of Medicine, Universitas Andalas, Komplek Kampus UNAND
Sumatera Barat, Indonesia

**Zulkifli Amin**
Faculty of Medicine, Universitas Indonesia; Division of Pulmonology and Critical Care, Department of Internal Medicine, National Central Public Hospital of Dr. Cipto Mangunkusumo
Jakarta, Indonesia